Analyst Ratings For Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
Today, Cantor Fitzgerald raised its price target on Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to $24.00 per share.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is Buy with a consensus target price of $21.3633 per share, a potential 41.01% upside.
Some recent analyst ratings include
- 10/4/2018-Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) had its Overweight rating reiterated by Piper Jaffray Companies with a $25.00 price target
- 9/6/2018-Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) gets upgraded to Buy by B. Riley with a price target of $19.00
- 9/18/2017-Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) gets upgraded to Outperform by William Blair
Recent Insider Trading Activity For Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has insider ownership of 4.60% and institutional ownership of 58.77%.
- On 9/6/2018 Kenneth Allen Myszkowski, CFO, sold 45,000 with an average share price of $19.34 per share and the total transaction amounting to $870,300.00.
- On 9/4/2018 Christopher Richard Anzalone, CEO, sold 164,834 with an average share price of $14.45 per share and the total transaction amounting to $2,381,851.30.
- On 8/31/2018 Christopher Richard Anzalone, CEO, sold 100,000 with an average share price of $14.45 per share and the total transaction amounting to $1,445,000.00.
- On 6/19/2018 Kenneth Allen Myszkowski, CFO, sold 20,000 with an average share price of $14.01 per share and the total transaction amounting to $280,200.00.
- On 5/31/2018 Kenneth Allen Myszkowski, CFO, sold 14,000 with an average share price of $11.00 per share and the total transaction amounting to $154,000.00.
- On 4/24/2018 Douglas B. Given, Director, sold 25,000 with an average share price of $6.63 per share and the total transaction amounting to $165,750.00.
- On 3/27/2018 Kenneth Allen Myszkowski, CFO, sold 20,000 with an average share price of $8.00 per share and the total transaction amounting to $160,000.00.
About Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Recent Trading Activity for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
Shares of Arrowhead Pharmaceuticals Inc closed the previous trading session at 15,32 −3,24 17,48 % with 20.3 shares trading hands.